Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

(2021) Justin F Gainor et al.   LANCET ONCOLOGY

Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience

(2021) Yong-Pyo Lee et al.   EUROPEAN JOURNAL OF CANCER

State-of-the-Art Strategies for Targeting RET-Dependent Cancers

(2020) Vivek Subbiah et al.   JOURNAL OF CLINICAL ONCOLOGY

Pulmonary toxicity of systemic lung cancer therapy

(2020) Kathryn Long et al.   RESPIROLOGY

Opportunistic Invasive Fungal Infections Mimicking Progression of Non-Small Cell Lung Cancer

(2020) Marian Park et al.   Clinical Lung Cancer

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives

(2020) Evgeny N. Imyanitov et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL)

(2019) Georg Maschmeyer et al.   LEUKEMIA

RET fusions in solid tumors

(2019) Andrew Y. Li et al.   CANCER TREATMENT REVIEWS

Precision Targeted Therapy with BLU-667 for RET -Driven Cancers

(2018) Vivek Subbiah et al.   Cancer Discovery

JAK1/2 inhibition impairs T cell functionin vitroand in patients with myeloproliferative neoplasms

(2015) Sowmya Parampalli Yajnanarayana et al.   BRITISH JOURNAL OF HAEMATOLOGY